SLRX - Salarius Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Houston,
United States
Type: Equity
SLRX price evolution
SLRX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.27 | $4.37 | $5.9 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $3.82 | $3.51 | $4.83 | $6.52 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.04 | $0.05 | $0.07 | |
| Total investments | ||||
| Total assets | $3.86 | $3.55 | $4.88 | $6.59 |
| Current liabilities | ||||
| Accounts payable | $0.17 | $0.64 | $0.71 | $0.6 |
| Deferred revenue | ||||
| Short long term debt | $0.12 | $0.29 | ||
| Total current liabilities | $0.93 | $1.18 | $1.23 | $1.3 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.12 | $0.29 | ||
| Total liabilities | $0.93 | $1.18 | $1.23 | $1.3 |
| Shareholders' equity | ||||
| Retained earnings | -$80.46 | -$79.49 | -$78.06 | -$76.35 |
| Other shareholder equity | ||||
| Total shareholder equity | $2.38 | $3.65 | $5.29 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.9 | $12.11 | $29.21 | $11.12 |
| Short term investments | ||||
| Net receivables | $1.61 | $1.61 | $3.86 | |
| Inventory | ||||
| Total current assets | $6.52 | $14.52 | $30.16 | $15.8 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $0.02 | ||
| Goodwill & intangible assets | $8.87 | $8.87 | ||
| Total noncurrent assets | $0.07 | $0.13 | $10.67 | $9.14 |
| Total investments | ||||
| Total assets | $6.59 | $14.65 | $40.83 | $24.93 |
| Current liabilities | ||||
| Accounts payable | $0.6 | $2.86 | $1.54 | $1.85 |
| Deferred revenue | ||||
| Short long term debt | $0.29 | $0.48 | ||
| Total current liabilities | $1.3 | $4.27 | $2.11 | $2.77 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.29 | $0.48 | ||
| Total liabilities | $1.3 | $4.27 | $2.11 | $2.77 |
| Shareholders' equity | ||||
| Retained earnings | -$76.35 | -$63.81 | -$32.2 | -$19.43 |
| Other shareholder equity | ||||
| Total shareholder equity | $5.29 | $10.38 | $38.72 | $22.16 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.21 | $0.24 | $0.06 | |
| Selling, general & administrative | $1.25 | $1.53 | $0.91 | |
| Total operating expenses | $1.01 | $1.47 | $1.77 | $0.97 |
| Operating income | -$1.47 | -$1.77 | -$0.97 | |
| Income from continuing operations | ||||
| EBIT | -$1.42 | -$1.72 | -$0.88 | |
| Income tax expense | ||||
| Interest expense | $0.03 | |||
| Net income | ||||
| Net income | -$0.97 | -$1.42 | -$1.72 | -$0.88 |
| Income (for common shares) | -$1.42 | -$1.72 | -$0.88 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.84 | $5.23 | ||
| Cost of revenue | ||||
| Gross Profit | $1.84 | $5.23 | ||
| Operating activities | ||||
| Research & development | $7.17 | $15.84 | $8.55 | $6.91 |
| Selling, general & administrative | $5.72 | $7.14 | $6.1 | $6.11 |
| Total operating expenses | $12.89 | $31.84 | $14.65 | $13.02 |
| Operating income | -$12.89 | -$31.84 | -$12.81 | -$7.79 |
| Income from continuing operations | ||||
| EBIT | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Income tax expense | ||||
| Interest expense | $0 | |||
| Net income | ||||
| Net income | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Income (for common shares) | -$12.54 | -$31.61 | -$12.77 | -$7.75 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.42 | -$1.72 | -$0.88 | |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.09 | $0.08 | $0.09 | |
| Total cash flows from operations | -$1.07 | -$1.35 | -$1.51 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.09 | $0 | -$0 | |
| Net borrowings | -$0.12 | -$0.17 | -$0.17 | |
| Total cash flows from financing | $1.17 | -$0.03 | -$0.17 | -$0.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.62 | -$1.1 | -$1.53 | -$1.68 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$12.54 | -$31.61 | -$12.77 | -$7.35 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$1.5 | |||
| Stock-based compensation | $0.52 | $0.8 | $0.56 | $0.32 |
| Total cash flows from operations | -$12.85 | -$17.6 | -$10.2 | -$10.31 |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$1.5 | -$0 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.92 | $1.99 | $27.29 | $14.8 |
| Net borrowings | -$0.28 | -$0.48 | -$0.97 | |
| Total cash flows from financing | $6.64 | $1.99 | $28.3 | $17.69 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.21 | -$17.11 | $18.1 | $7.38 |
News
Fundamentals
| Market cap | $1.02M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.44M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$4.99M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.21 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.47 |
|---|---|
| ROA | -105.78% |
| ROE | N/A |
| Debt/Equity | 0.25 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.09 |
| Quick ratio | N/A |